Ibrance (palbociclib) vs Kadcyla (trastuzumab emtansine)
Ibrance (palbociclib) vs Kadcyla (trastuzumab emtansine)
Ibrance (palbociclib) is a CDK4/6 inhibitor used primarily in combination with hormonal therapies for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Kadcyla (trastuzumab emtansine) is an antibody-drug conjugate specifically designed to target HER2-positive breast cancers, delivering chemotherapy directly to cancer cells that overexpress HER2. The choice between Ibrance and Kadcyla would depend on the specific biomarkers of the breast cancer being treated; Ibrance is suitable for HR-positive, HER2-negative cases, while Kadcyla is tailored for patients with HER2-positive tumors.
Difference between Ibrance and Kadcyla
Metric | Ibrance (palbociclib) | Kadcyla (trastuzumab emtansine) |
---|---|---|
Generic name | Palbociclib | Ado-trastuzumab emtansine |
Indications | Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer | HER2-positive metastatic breast cancer |
Mechanism of action | CDK4/6 inhibitor, halts cell cycle progression | HER2-targeted antibody-drug conjugate, disrupts microtubule networks |
Brand names | Ibrance | Kadcyla |
Administrative route | Oral | Intravenous |
Side effects | Neutropenia, leukopenia, infections, fatigue | Fatigue, nausea, musculoskeletal pain, thrombocytopenia |
Contraindications | Hypersensitivity to palbociclib or any of its components | Hypersensitivity to trastuzumab emtansine or any of its components |
Drug class | Antineoplastic agent, kinase inhibitor | Antineoplastic agent, antibody-drug conjugate |
Manufacturer | Pfizer | Genentech (Roche) |
Efficacy
Efficacy of Ibrance (Palbociclib) in Breast Cancer
Ibrance (palbociclib) is a targeted therapy known as a cyclin-dependent kinase (CDK) 4/6 inhibitor used in the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The efficacy of Ibrance, in combination with an aromatase inhibitor or fulvestrant, has been demonstrated in several clinical trials. These trials have shown that Ibrance significantly extends progression-free survival when compared to placebo, meaning patients treated with Ibrance experience a longer period before their disease worsens.
One of the pivotal studies for Ibrance's approval was the PALOMA-2 trial, which showed that the combination of Ibrance and letrozole significantly improved progression-free survival compared to letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer. The median progression-free survival was notably longer in the Ibrance group, highlighting its efficacy in delaying disease progression.
Efficacy of Kadcyla (Trastuzumab Emtansine) in Breast Cancer
Kadcyla (trastuzumab emtansine) is an antibody-drug conjugate that combines the HER2 targeting properties of trastuzumab with the chemotherapy agent DM1 (emtansine). Kadcyla is specifically designed for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, separately or in combination. It is also used in patients with early HER2-positive breast cancer who have residual invasive disease after neoadjuvant treatment. Clinical trials have shown that Kadcyla significantly improves survival outcomes in these patients.
In the pivotal EMILIA study, Kadcyla improved overall survival and progression-free survival in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane chemotherapy. Patients receiving Kadcyla had a significant improvement in median overall survival compared to those receiving the standard therapy of lapatinib plus capecitabine. Furthermore, Kadcyla has been associated with a reduction in the risk of disease recurrence in the adjuvant setting for early-stage HER2-positive breast cancer, as evidenced by the KATHERINE trial. This trial demonstrated that Kadcyla significantly improved invasive disease-free survival compared to trastuzumab in patients with residual invasive disease after neoadjuvant therapy.
Regulatory Agency Approvals
Ibrance
Kadcyla
Access Ibrance or Kadcyla today
If Ibrance or Kadcyla are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us